Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. The trial did not achieve statistical significance on the primary endpoint, which was defined as the proportion of patients with baseline CRP

Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen Announces Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 patients with Lenzilumab Guided by C-Reactive Protein

Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, confirms that notice was received today from the National Institute of Allergy and Infectious Diseases (NIAID) that they have completed database lock for the Big Effect Trial of lenzilumab (BET-B) being conducted as part of the National Instit

NIH/NIAID Locks ACTIV-5/BET-B Database

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreeme

Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' announced today that representatives will present and participate at multiple investors conferences in June 2022. Details of the conferences are as follows: LD Micro Invitational XII Ken Trbovich, SVP Investor Relations, will make an in-person corporate presentation at 11:00am EDT on

Humanigen Announces Participation and Presentation at Multiple Conferences in June

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT today at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022. In his presentation Dr. Durrant will provide an update on progress towards releas

Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference

KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of 34.69% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “A key highlight of the first quarter was the completion of enrollment in the ACTIV-5/BET-B study. We also held a productive Type B

Humanigen Reports First Quarter 2022 Financial Results

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' announced today that management will present and participate at multiple investors conferences in May 2022. Details of the conferences are as follows: LSX World Congress Tim Morris, COO & CFO, will provide an in-person corporate presentation at 10:45am EDT in London at the LSX World Co

Humanigen Announces Participation and Presentation at Multiple Conferences in May

SHORT HILLS, N.J.--(BUSINESS WIRE)--Study shows GM-CSF knockout aids CAR-T cell early activation, reduces activation induced cell death, and enhances anti-tumor activity in a mouse model

GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia

SHORT HILLS, N. J.--(BUSINESS WIRE)--Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

Bone Biologics Corp

Kiora Pharmaceuticals

Ra Medical Systems Inc

Biotech penny stocks to watch right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Biotech Stocks To Watch Right Now

Altamira Therapeutics Ltd

Kala Pharmaceuticals

Arcadia Biosciences

Nasdaq Penny Stocks List For March The post 4 Nasdaq Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Nasdaq Penny Stocks To Buy For Under $5

SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab, today reported financial results for the year ended December 31, 2021, and announced corporate objectives for 2022. Cameron Durrant, chairman and chief executive officer of Humanigen stated, “We initiated the development of lenzilumab, or LENZ®, in M

Humanigen Reports Year-End 2021 Financial Results

SHORT HILLS, N.J. & DUBLIN & LONDON & MELBOURNE, Australia--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that management will present and participate at several events in March with investors, analysts, bankers and potential partners. The goal of the events is to update participants regarding the company's progress in developing lenzilumab for COVID

Humanigen to Present and Participate at Multiple Investor Events in March

BURLINGAME, Calif. & DUBLIN & LONDON--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th. Hosted annually by the Biotechnology Innovation Organization (BIO) fo

Humanigen to Present at BIO CEO & Investor Conference

BURLINGAME, Calif. & DUBLIN & LONDON--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program (“LenzMAP™”). Clinigen Group plc (“Clinigen”), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Inc HGEN has selected Cenexi as a preferred supplier of lenzilumab in France and the European Union.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Humanigen, Cenexi Ink Manufacture Pact For COVID-19 Candidate, Lenzilumab, In France

BURLINGAME, Calif. & FONTENAY-SOUS-BOIS, France--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' and Cenexi, a French CDMO specializing in the formulation, analytical development, and manufacture of complex molecule drugs, announced a collaboration aimed at making Cenexi a preferred supplier of lenzilumab in France and the European Union. The initial ste

Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France

BURLINGAME, Calif.--(BUSINESS WIRE)---- $HGEN--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' today announced a peer-reviewed publication in the Journal of Medical Economics (https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2030148) citing the clinical and associated health economic benefits of lenzilumab. The publication demonstrated, in all cases, lenzilumab plus SOC

Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab

KaloBios Pharmaceuticals Inc. (HGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KaloBios Pharmaceuticals Inc. (HGEN) Upgraded to Buy: Here's What You Should Know

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' today outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma (rrNHL). “Following recent constructive interaction with FDA on th

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm', announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved. The study, sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, enrolled over 400 patients in the primary analysis population at approxim

Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

BURLINGAME, Calif.--(BUSINESS WIRE)---- $HGEN--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that Cameron Durrant, chairman and chief executive officer of Humanigen, will present at two healthcare conferences in January 2022. The company and its management are also expected to meet with investors, analysts, bankers and potential partners during the conferences next wee

Humanigen to Present at Investor Conferences January 7 and 13, 2022

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, announced that a manuscript detailing the results of an analysis of CRP levels from the LIVE-AIR Phase 3 study is available on medRxiv (https://www.medrxiv.org/content/10.1101/2021.12.30.21267140v1) . The results indicate the greatest clinical bene

News for Humanigen Stock (HGEN)